Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

Lundbeck Australia Pty Ltd

By Australian Hospital + Healthcare Bulletin Staff
Tuesday, 17 October, 2017


Rexulti group 02

October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia. REXULTI works on three neurotransmitter systems: serotonin, dopamine and noradrenaline.1

The efficacy and safety of REXULTI have been demonstrated in two short-term studies and one long-term maintenance trial.1

REXULTI tablets are taken once daily and come in dose strengths of 1 mg, 2 mg, 3 mg and 4 mg with a recommended target dose of 2-4 mg/day.

Lundbeck Australia and Otsuka Australia Pharmaceutical are dedicated to bringing innovative new medicines to Australians with psychiatric disorders.

Please review the REXULTI Approved Product Information before prescribing. Product information is available by calling Lundbeck on 1300 721 277 or click here.

1. REXULTI® Australian Approved Product Information.

Related Sponsored Contents

Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the...

Register now for ACIPC 2017, 20 – 22 November 2017, Canberra ACT

The ACIPC International Conference is Australasia's pre-eminent conference for Infection...

Hospital Disinfection: Reducing HAI rates

Environmental cleaning and disinfection is a unique challenge.


  • All content Copyright © 2017 Westwick-Farrow Pty Ltd